ADAPTIVE BIOTECHNOLOGIES CORPORATION Shareholders' Equity
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Shareholders' Equity of $142.91 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $142.91M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $216.34M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $218.79M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $204.44M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $142.91M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $216.34M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $218.79M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $204.44M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $179.72M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $190.42M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $202.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $223.77M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $241.60M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $274.91M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $308.40M 10-K · filed 2025-03-03 |
| 2023-09-30 | $361.73M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $396.04M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $424.02M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $464.17M 10-K · filed 2024-02-29 |
| 2022-09-30 | $487.84M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $518.30M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $553.21M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $603.99M 10-K · filed 2023-02-14 |
| 2021-09-30 | $651.51M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $693.18M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $725.59M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $743.27M 10-K · filed 2022-02-15 |
| 2020-09-30 | $775.05M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $529.94M 10-Q · filed 2020-11-10 |
| 2020-03-31 | $551.56M 10-Q · filed 2020-08-10 |
| 2019-12-31 | $571.04M 10-K · filed 2021-02-24 |
| 2019-09-30 | $585.92M 10-Q · filed 2020-11-10 |
| 2019-06-30 | -$284.37M 10-Q · filed 2020-11-10 |
| 2019-03-31 | -$273.47M 10-Q · filed 2020-08-10 |
| 2018-12-31 | -$258.11M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$248.08M 10-Q · filed 2019-11-12 |
| 2018-06-30 | -$242.44M 10-Q · filed 2019-11-12 |
| 2018-03-31 | -$233.61M 10-Q · filed 2019-08-13 |
| 2017-12-31 | -$224.62M 10-K · filed 2021-02-24 |
| 2016-12-31 | -$189.73M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |